Aurora Cannabis reports revenue of CA$99 million, with CA$4 million in global sales

Aurora Cannabis reports revenue of CA$99 million, with CA$4 million in global sales

Alberta-based Aurora Cannabis reported net revenue of 99 million Canadian dollars ($75 million) in its most recent quarter, but international sales amounted to only CA$4 million.

Aurora was edged in revenue by rival producer Canopy Growth, which reported CA$94 million in its most recent quarter.

However, Aurora saw improvements across the board in its fiscal fourth quarter that ended June 30, including in the medical cannabis sector.

The company’s medical cannabis patient base grew to 89,700 active registered patients – or about a quarter of Canada’s 364,000 patients.

That helped boost the company’s medical cannabis sales by 12% to almost CA$30 million.

By comparison, Canopy’s active registered patient list dropped to 70,900 in its latest quarter on medical cannabis revenue of CA$13 million.

Aurora continued to make strides in the adult-use market.

The company reported Canadian consumer revenue of CA$45 million, up 52% from the company’s fiscal third quarter.

Production volume – a key indicator of how well the company is scaling up – grew to 29,034 kilograms (64,009 pounds), an increase of 86% over the previous quarter.

Aurora’s adjusted EBITDA loss of CA$11.7 is an improvement over the previous quarter’s CA$36 million loss.

In its regulatory filing, Aurora noted that it continues to track toward positive adjusted EBITDA:

“While profitability remains a very important target for Aurora, we expect that the inherent volatility of revenue ramp-up in the developing cannabis industry, and the necessary investment to develop and manufacture new products for the Canadian consumer market, may result in near-term challenges to achieving positive adjusted EBITDA.”

The company’s net loss in the latest quarter was CA$2.3 million.

Aurora’s international sales rose only CA$500,000 in the quarter and now make up 5% of net revenue.

However, where Aurora previously cited “supply shortages for export,” the company now claims “supply shortages in Europe.”

“While we continue to expand our business into international markets, we have faced supply shortages in Europe,” according to the filing.

“Our ability to allocate more product to international markets in 2019 is increasing significantly as we continue to develop our international infrastructure and distribution channels as more of our facilities become European Union Good Manufacturing Practice certified.”

Aurora’s shares trade as ACB on the New York Stock Exchange and the Toronto Stock Exchange.

Matt Lamers can be reached at [email protected]

For analysis and in-depth looks at the investment trends and deals driving the cannabis industry forward, sign up for our premium subscription service, Investor Intelligence.

Published at Wed, 11 Sep 2019 22:30:57 +0000

Comments are closed.